or Try an Advanced Search...

    Viral Disease Stocks List

    Symbol Grade Name % Change
    ALVR B AlloVir, Inc. 2.52
    TRIB C Trinity Biotech plc -3.98
    VRAX D Virax Biolabs Group Limited -1.45
    ALGS F Aligos Therapeutics, Inc. -2.35
    NNVC F NanoViricides, Inc. -0.70
    HOOK F HOOKIPA Pharma Inc. 1.32
    EVAX F Evaxion Biotech A/S -3.00
    IVVD F Invivyd, Inc. 2.36
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biotechnology Clinical Medicine Hepatitis B Medicine Infectious Diseases Viral Infections Virus Viruses Antibodies Biology Biopharmaceutical Cancer Coronavirus HIV Hepatitis Hepatitis B Virus Herpes Herpes Simplex Immunodeficiency Immunology

    Related ETFs - A few ETFs which own one or more of the above listed Viral Disease stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.02
    IWN C iShares Russell 2000 Value ETF 0.01
    FESM B Fidelity Enhanced Small Cap ETF 0.01
    VXF A Vanguard Extended Market ETF 0.0
    VTI B Vanguard Total Stock Market ETF 0.0
    View all Viral Disease ETFs...
    Compare ETFs
    Compare FESM to VTI Compare IWC to FESM Compare IWN to FESM

        Viral Disease Stocks Recent News

        Date Stock Title
        Oct 31 HOOK HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
        Oct 31 EVAX Evaxion Biotech ADS GAAP EPS of -$0.04, revenue of $3.01M
        Oct 31 EVAX Evaxion announces business update and third quarter 2024 financial results
        Oct 31 EVAX EVAX Exceeds Estimates and Confirms Partnership
        Oct 30 ALVR Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
        Oct 30 ALGS Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
        Oct 30 HOOK HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
        Oct 29 IVVD Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M
        Oct 29 IVVD Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
        Oct 29 IVVD Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
        Oct 28 EVAX Evaxion to announce business update and third quarter 2024 financial results on October 31
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biotechnology Clinical Medicine Hepatitis B Medicine Infectious Diseases Viral Infections Virus Viruses Antibodies Biology Biopharmaceutical Cancer Coronavirus HIV Hepatitis Hepatitis B Virus Herpes Herpes Simplex Immunodeficiency Immunology
        Viral Disease

        Viral diseases are illnesses caused by a virus, which is a microscopic organism that can infect a person, animal, or plant. Common examples of viral diseases include the flu, the common cold, chickenpox, HIV/AIDS, and Ebola.

        Browse All Tags